Record sales month in New Zealand and Australia

8 October 2025

FOR PUBLIC RELEASE

Record sales month in New Zealand and Australia
September was a milestone month for Rua Bioscience, delivering record sales across both our
New Zealand and Australian markets. This achievement reflects the continued momentum
behind Rua’s growth strategy - working closely with trusted cultivators to deliver high-quality
products consistently to prescribers and pharmacies in key markets.
In Australia, our record sales demonstrate growing demand and confidence in Rua’s product
portfolio. This performance is particularly encouraging given the highly competitive nature of
the market and underscores the strength of the sales and distribution partnerships we have built
over the past 18 months. It’s a key market in our international expansion strategy and these
relationships are now translating into tangible results. This is providing a solid foundation for
sustained growth.
In Aotearoa New Zealand, Rua continues to strengthen its position as the market evolves. The
expansion of our high-quality product range has been well received by prescribers and patients
alike, driving record domestic sales in September. Our teams’ efforts to deepen engagement
with clinics and pharmacies nationwide are resulting in consistent volume growth and enhanced
presence across Aotearoa.

The overall medicinal cannabis market in New Zealand is experiencing steady growth. Data
from the NZ Ministry of Health to June 2025 shows a steady increase in the number of medicinal
0
20,000
40,000
60,000
80,000
100,000
120,000
Qtr1Qtr2Qtr3Qtr4Qtr1Qtr2Qtr3Qtr4Qtr1Qtr2Qtr3Qtr4Qtr1Qtr2
2022202320242025
Units of medicinal cannabis products prescribed in NZ

cannabis products prescribed as more prescribers become comfortable integrating these
therapies into patient care.
Czech Republic - New market entry
September marked another milestone with the official entry into the Czech Republic, a growing
European medicinal cannabis market. In partnership with our distributor, Motagon, we have
launched our first Rua product. Initial prescriptions are already being filled, and this marks the
beginning of a new revenue stream and a foothold in Central Europe.
The Czech Republic is part of our longer-term strategy to establish Rua Bioscience in well-
regulated, growth-ready markets. By working closely with trusted, in-market partners, we’re
setting up a scalable pipeline for future products, while maintaining a lean cost structure.

Germany – Sales recovering after supply gap
After a brief period of being out of stock, sales in Germany have resumed and are steadily
growing. Prescriber demand remains strong, and we’re working closely with our distribution
partners to ensure more consistent supply moving forward. Germany remains one of our most
promising markets in terms of scale and reimbursement access, and we’re focused on building
reliability and trust as our presence grows.
United Kingdom – Early-stage momentum
The UK market remains in its early stages for Rua, with brand presence and prescriber
relationships still developing. Revenue is small but growing, and we continue to see value in
building a foundation in this market, particularly as regulatory and clinical pathways mature.
Looking ahead
Our significant progress across New Zealand, Australia, and now launching in the Czech
Republic reflects the strength of Rua’s focused, capital-conscious approach. With revenue
pipelines now in five markets we are building momentum and resilience in our business model.
And most importantly, supporting more patients with high-quality, consistent medicinal
cannabis products.
As always, thank you for your ongoing support as we continue to grow Rua Bioscience into a
globally connected, proudly Te Ta i ra w h i t i-founded medicinal cannabis company.

ENDS
The person who authorised this statement:
Paul Naske
Chief Executive Officer
paul.naske@ruabio.com
+64 21 445154